Clinical Trial Update: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating subcutaneous epcoritamab as monotherapy or with standard-of-care therapies in adults in China with B-cell non-Hodgkin lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Epcoritamab (epcoritamab)

Snippet

Sponsor: Genmab | Conditions: B-Cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING